Abbott: Abbott Labs: 11% increase in Q1 EPS

Abbott Laboratories reports an 11.2% increase in adjusted EPS to $1.09 for Q1 2025, based on an adjusted operating margin that improved 130bp to 21%. The healthcare group's revenues rose 4% to nearly $10.4bn as reported, and by 6.9% in organic terms (and +8.5% excluding sales related to Covid-19 tests), notably driven by medical devices (+12.6% in organic terms). For FY 2025, Abbott Labs confirms that expects adjusted EPS of $5.05 to $5.25, an adjusted operating margin of 23.5% to 24% (+150bp in the middle of this range) and organic revenue growth of 7.5% to 8.5%. Copyright (c) 2025 CercleFinance.com. All rights reserved. Abbott Laboratories reports an 11.2% increase in adjusted EPS to $1.09 for Q1 2025, based on an adjusted operating margin that improved 130bp to 21%. The healthcare group's revenues rose 4% to nearly $10.4bn as reported, and by 6.9% in organic terms (and +8.5% excluding sales related to Covid-19 tests), notably driven by medical devices (+12.6% in organic terms). For FY 2025, Abbott Labs confirms that expects adjusted EPS of $5.05 to $5.25, an adjusted operating margin of 23.5% to 24% (+150bp in the middle of this range) and organic revenue growth of 7.5% to 8.5%. Copyright (c) 2025 CercleFinance.com. All rights reserved.